CA2984153A1 - 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto - Google Patents

1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto Download PDF

Info

Publication number
CA2984153A1
CA2984153A1 CA2984153A CA2984153A CA2984153A1 CA 2984153 A1 CA2984153 A1 CA 2984153A1 CA 2984153 A CA2984153 A CA 2984153A CA 2984153 A CA2984153 A CA 2984153A CA 2984153 A1 CA2984153 A1 CA 2984153A1
Authority
CA
Canada
Prior art keywords
pyridin
indoline
carboxamide
fluoro
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2984153A
Other languages
English (en)
French (fr)
Inventor
Yifeng Xiong
Andrew J. Grottick
Henry KORMAN
Juerg Lehmann
Albert S. Ren
Graeme Semple
Didier Jc Bagnol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CA2984153A1 publication Critical patent/CA2984153A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA2984153A 2015-04-29 2016-04-29 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto Abandoned CA2984153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154523P 2015-04-29 2015-04-29
US62/154,523 2015-04-29
PCT/US2016/030105 WO2016176571A1 (en) 2015-04-29 2016-04-29 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto

Publications (1)

Publication Number Publication Date
CA2984153A1 true CA2984153A1 (en) 2016-11-03

Family

ID=56015108

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2984153A Abandoned CA2984153A1 (en) 2015-04-29 2016-04-29 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto

Country Status (15)

Country Link
US (1) US9676758B2 (enExample)
EP (1) EP3292114B1 (enExample)
JP (1) JP6673939B2 (enExample)
KR (1) KR20180004193A (enExample)
CN (1) CN108174603B (enExample)
AU (1) AU2016255510A1 (enExample)
BR (1) BR112017022987A2 (enExample)
CA (1) CA2984153A1 (enExample)
CL (1) CL2017002738A1 (enExample)
EA (1) EA034244B1 (enExample)
ES (1) ES2784316T3 (enExample)
IL (1) IL255185A0 (enExample)
MX (1) MX373876B (enExample)
PH (1) PH12017501961A1 (enExample)
WO (1) WO2016176571A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111792990A (zh) * 2019-04-09 2020-10-20 中国科学院上海药物研究所 一种不饱和酮类化合物、其制备方法和用途
BR112022008685A2 (pt) 2019-11-08 2022-07-26 Heptares Therapeutics Ltd Compostos moduladores de gpr52
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
PE20221918A1 (es) * 2020-03-30 2022-12-29 Boehringer Ingelheim Int 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
US12421193B2 (en) 2020-04-22 2025-09-23 Neurocrine Biosciences, Inc. GPR52 modulators and methods of use
GB202013558D0 (en) * 2020-08-28 2020-10-14 Heptares Therapeutics Ltd GRP52 Modularor compounds
EP4330232A1 (en) 2021-04-26 2024-03-06 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
CN117940420A (zh) 2021-09-14 2024-04-26 勃林格殷格翰国际有限公司 3-苯氧基氮杂环丁烷-1-基-杂芳基吡咯烷衍生物及其作为药物的用途
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
AR130864A1 (es) * 2022-10-26 2025-01-29 Neurocrine Biosciences Inc Compuestos y composiciones como moduladores de gpr52
TW202425979A (zh) * 2022-10-26 2024-07-01 美商紐羅克里生物科學有限公司 作為gpr52調節劑之化合物及組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043744A2 (en) * 2006-07-13 2009-04-08 SmithKline Beecham Corporation Chemical compounds
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2298731A4 (en) * 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
UY32045A (es) 2008-08-12 2010-03-26 Takeda Pharmaceutical Compuesto amida
JP2012530758A (ja) * 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
JP2012082175A (ja) * 2010-10-14 2012-04-26 Daiichi Sankyo Co Ltd インドリン化合物を含有する医薬組成物

Also Published As

Publication number Publication date
EP3292114A1 (en) 2018-03-14
EA034244B1 (ru) 2020-01-21
AU2016255510A1 (en) 2017-11-23
EP3292114B1 (en) 2020-03-11
ES2784316T3 (es) 2020-09-24
CN108174603B (zh) 2021-07-02
PH12017501961A1 (en) 2018-03-26
IL255185A0 (en) 2017-12-31
CL2017002738A1 (es) 2018-06-01
WO2016176571A1 (en) 2016-11-03
CN108174603A (zh) 2018-06-15
KR20180004193A (ko) 2018-01-10
EA201792375A1 (ru) 2018-05-31
JP6673939B2 (ja) 2020-04-01
JP2018519253A (ja) 2018-07-19
US20160318911A1 (en) 2016-11-03
US9676758B2 (en) 2017-06-13
MX2017013853A (es) 2018-06-07
MX373876B (es) 2020-03-26
BR112017022987A2 (pt) 2018-07-24

Similar Documents

Publication Publication Date Title
US9676758B2 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto
JP6429954B2 (ja) Fgfr4阻害剤としての縮環二環式ピリジル誘導体
TWI549947B (zh) 治療化合物及組成物
TWI473803B (zh) 作為阿伐7正向異位調節劑之嗎福啉基噻唑
RU2683245C1 (ru) 6-членные гетероциклические производные и содержащая их фармацевтическая композиция
JP2019031537A (ja) エストロゲン受容体調節剤としての6,7−ジヒドロ−5h−ベンゾ[7]アヌレン誘導体
CA2770932C (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
EP3810608A1 (en) Oga inhibitor compounds
JP2014509660A (ja) PDK1キナーゼの阻害剤としての置換3−(1H−ベンゾ{d}イミダゾール−2−イル)−1H−インダゾール類似体
JP2013523766A (ja) キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
KR20180080245A (ko) 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법
JP2020506940A (ja) Oga阻害化合物
CA2652852A1 (fr) Derives d'urees de piperidine ou pyrrolidine, leur preparation et leur application en therapeutique
EP3981394A1 (en) A sortilin antagonist for use in the prevention or treatment of hearing loss.
AU2022339056A1 (en) 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system
JP6768674B2 (ja) 新規ベンズイミダゾール化合物およびその医薬用途
CN103037693A (zh) 作为mglur5正向变构调节剂的取代的6-甲基烟酰胺
JP5947897B2 (ja) N−ピペリジン−4−イル誘導体
KR20220118483A (ko) Oga 억제제 화합물
TWI564300B (zh) 經取代之[(5H-吡咯[2,1-c][1,4]苯二氮呯-11-基)哌嗪-1-基]-2,2-二甲基丙酸化合物作為雙重活性H1反向促進劑/5-HT2A拮抗劑
KR20240042472A (ko) 무스카린성 수용체 4 길항제 및 사용 방법
EA010893B1 (ru) Новые производные бензоилмочевины
TW200403239A (en) Novel compounds

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220720

FZDE Discontinued

Effective date: 20220720